These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1942558)

  • 21. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
    Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
    Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
    Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M
    Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
    Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
    Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological activity of the main metabolites of ubenimex in humans.
    Abe F; Kuramochi H; Takahashi K; Ishizuka M; Takeuchi T
    J Antibiot (Tokyo); 1988 Dec; 41(12):1862-7. PubMed ID: 3209478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.
    Ohno R; Tatsumi N; Hirano M; Imai K; Mizoguchi H; Nakamura T; Kosaka M; Takatsuki K; Yamaya T; Toyama K
    Oncology; 1991; 48(6):451-5. PubMed ID: 1749580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
    Wijermans PW; Krulder JW; Huijgens PC; Neve P
    Leukemia; 1997 Jan; 11(1):1-5. PubMed ID: 9001409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
    Guan M; Chen SC; Li RS; Ge CW; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ubenimex, a biological response modifier, on myelodysplastic syndrome and chronic leukemia.
    Tatsumi N; Sannomiya Y; Sasaki A; Im T; Ota K; Oohira H; Nakao H; Yasui Y
    Biomed Pharmacother; 1991; 45(2-3):95-103. PubMed ID: 1912374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
    Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
    Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of myelodysplastic syndrome with cyclosporin A.
    Chen S; Jiang B; Da W; Gong M; Guan M
    Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical observation on treatment of myelodysplastic syndromes with yisuikang].
    Guo PJ; Li GZ; Liu PL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1995 Feb; 15(2):74-6. PubMed ID: 7787394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.